Parabilis Medicines, Inc. (PBLS)

Parabilis Medicines Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2025	Dec 31, 2024
Net Income	-152.88	-186.93	-161.48
Depreciation & Amortization	2.45	2.5	2.11
Share-Based Compensation	-	3.32	4.31
Other Operating Activities	11.67	16.36	7.88
Operating Cash Flow	-138.76	-123.71	-103.61
Capital Expenditures	-0.6	-0.31	-0.88
Change in Investments	-	40.06	31.12
Investing Cash Flow	32.7	39.76	30.24
Share Issuance / Repurchase	-	67.46	78.09
Debt Issued / Paid	-	3.08	-
Other Financing Activities	347.99	-6.16	-0.02
Financing Cash Flow	347.99	64.38	78.07
Net Cash Flow	241.93	-19.57	4.7
Free Cash Flow	-139.36	-124.02	-104.49

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).